Abstract Number: 2379 • 2019 ACR/ARP Annual Meeting
High Initial Methotrexate Dose Is Not Associated with an Increased Risk of Liver Toxicity in Korean Patients with Rheumatoid Arthritis
Background/Purpose: Methotrexate (MTX) is the most commonly prescribed disease modifying anti-rheumatic drugs (DMARDs) for the treatment of RA due to its high efficacy and favorable…Abstract Number: 2460 • 2019 ACR/ARP Annual Meeting
Frailty in Ankylosing Spondylitis, Psoriatic Arthritis, and Rheumatoid Arthritis: Data from a National Claims Database
Background/Purpose: Frailty, a state of decreased homeostatic reserve, is associated with increased disability and mortality, independent of age. Frailty has been evaluated in large datasets…Abstract Number: 2850 • 2019 ACR/ARP Annual Meeting
Exploring Heterogeneity in Rheumatoid Arthritis: Outcomes up to 4 Years of Follow-Up in Patient Clusters Identified by Data-driven Analysis of the BRASS Registry
Background/Purpose: Patients with rheumatoid arthritis (RA) may share characteristics that relate to their future outcomes. We investigated clinical outcomes over a 4-year follow-up period in…Abstract Number: 7 • 2019 ACR/ARP Annual Meeting
Citrullination of Interleukin 6 Augments Its Pro-inflammatory Capacity and Signaling Potency Through Interleukin-6 Receptor in Rheumatoid Arthritis
Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory disorder featured by synovial hyperplasia, inflammatory cell infiltration and presence of anti-citrullinated peptide antibodies (ACPAs) in sera.…Abstract Number: 58 • 2019 ACR/ARP Annual Meeting
In Rheumatoid Arthritis (RA) Decreases in Conventional Dendritic Cell Lineages Are Associated with Adverse Measures of Myocardial Function and Expansions of Anomalous HLA-DR+ Myeloid Subsets
Background/Purpose: Dendritic cells (DC) are specialized antigen-presenting cells (APC) that have a central role in the initiation of immune responses. However, prior studies showed numeric decreases…Abstract Number: 189 • 2019 ACR/ARP Annual Meeting
Validation of Claims-based Algorithms to Identify Interstitial Lung Disease in Patients with Rheumatoid Arthritis
Background/Purpose: The prevalence of interstitial lung disease (ILD) among rheumatoid arthritis (RA) patient ranges between 5-10%. ILD leads to high morbidity and mortality in patients…Abstract Number: 280 • 2019 ACR/ARP Annual Meeting
Ultrasound versus Conventional Treat-To-Target Strategies in Early Rheumatoid Arthritis: Magnetic Resonance Imaging Outcome Data from a 2-year Randomized Controlled Strategy Trial
Background/Purpose: It has been debated whether treatment outcomes in early RA would be improved by targeting imaging remission, assessed by ultrasound or MRI, in addition…Abstract Number: 447 • 2019 ACR/ARP Annual Meeting
Nail Abnormalities in a Cohort of Rheumatoid Arthritis Patients: Repetitive Trauma-Related Findings in Toenails Are Associated with Radiographic Damage
Background/Purpose: Different dermatological changes and nail abnormalities have been reported in rheumatoid arthritis (RA) patients, some of which are specifically associated with the disease, while…Abstract Number: 473 • 2019 ACR/ARP Annual Meeting
RA Presents in Disease Patterns Impacting Treatment Response
Background/Purpose: Despite significant research on rheumatoid arthritis (RA), disease courses have not been clearly described. Like systemic lupus erythematosus and multiple sclerosis, RA displays a…Abstract Number: 523 • 2019 ACR/ARP Annual Meeting
The Impact of Upadacitinib versus Methotrexate or Adalimumab on Individual and Composite Disease Measures in Patients with Rheumatoid Arthritis
Background/Purpose: In Phase 3 trials, upadacitinib (UPA), an oral JAK1-selective inhibitor, has been assessed as monotherapy vs MTX (SELECT-EARLY1) and in combination with MTX vs…Abstract Number: 819 • 2019 ACR/ARP Annual Meeting
The Long Noncoding RNA HOTTIP Regulates Cell Cycle and Inflammatory Response in Hand Synovial Fibroblasts
Background/Purpose: Previously we showed that the long noncoding RNA (lncRNA) HOTTIP is exclusively expressed in synovial fibroblasts (SF) from distal joints, such as small joints…Abstract Number: 926 • 2019 ACR/ARP Annual Meeting
Methotrexate Is Associated with Reduced Cardiovascular Risk in Rheumatoid Arthritis Independent of Disease Activity Modification
Background/Purpose: Rheumatoid arthritis (RA) patients are at increased risk of cardiovascular disease (CVD). Methotrexate (MTX), a mainstay in the treatment of RA, appears to mitigate…Abstract Number: 1133 • 2019 ACR/ARP Annual Meeting
Medicare Spending (2012-2017) on Disease Modifying Agents Commonly Used in Rheumatoid Arthritis
Background/Purpose: Biologic disease modifying agents (DMARDs) have become an integral part of rheumatoid arthritis (RA) treatment guidelines, but they are associated with a substantial increase…Abstract Number: 1335 • 2019 ACR/ARP Annual Meeting
Tumor Necrosis Factor Alpha Inhibitor (TNF-α Inhibitor) Exposure and Risk of Hip Fracture in Veterans with Rheumatoid Arthritis: A Nested Case Control Study
Background/Purpose: Patients with rheumatoid arthritis (RA) have a much greater risk of sustaining a hip fracture than those without RA. Hip fractures cause significant morbidity…Abstract Number: 1362 • 2019 ACR/ARP Annual Meeting
Relationship Between Waking Functions and Disease Activity in Rheumatoid Arthritis Patients Analyzed by Wearable Device
Background/Purpose: We reported that the prevalence of sarcopenia was 28% and locomotive syndrome was 52% in patients with rheumatoid arthritis (RA)1. It is unknown that…
- « Previous Page
- 1
- …
- 7
- 8
- 9
- 10
- 11
- …
- 56
- Next Page »